DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...

The following is a summary of “Randomized Study Comparing Continuous Glucose Monitoring and Capillary Glucose Testing in Patients With Type 2 Diabetes After Hospital Discharge,” published in the March ...

The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...

One of the company’s biggest growth engines has been its FreeStyle Libre franchise in the diabetes care segment, which includes a variety of continuous glucose monitoring (CGM) devices and has ...

A new randomised clinical trial – carried out by researchers at the University of Bath in the UK – found that a CGM sold by Abbott (the Freestyle Libre 2) "systemically overestimated" glucose ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

Abbott's ABT diversified business portfolio is well-positioned to drive momentum. However, the international business environment continues to be challenging globally. The stock carries a Zacks Rank ...

Savefor later Page saved! You can go back to this later in your Diabetes and Me Close ...